Expanded Access to Telisotuzumab Vedotin

AbbVie

Status

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Treatments: Drug: Telisotuzumab vedotin

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04830202

C20-503

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Exclusion Criteria:

• There are other suitable treatment options.
• The participant qualifies for ongoing clinical trials.